N8 Medical Release: Recently Published Study Demonstrates That CSA-90 May Promote Osteogenesis And Prevent Staphylococcus Aureus Infection In Preclinical Models
COLUMBUS, Ohio, March 4, 2015 (GLOBE NEWSWIRE) -- N8 Medical, an emerging pharmaceutical company addressing life-threatening global health challenges through the development of high-value pharmaceutical and antimicrobial device solutions based on a patented, first-in-class small molecule technology, announces the recent publication of a study in the Journal of Bone and Joint Surgery that demonstrates that the company's ceragenin-based CSA-90 promotes union of fractured bone while preventing infection in mouse models.
In vitro study results showed that CSA-90 increased matrix mineralization and potentiated rhBMP-2 activity in cultured osetoblasts. When CSA-90 was administered locally to mice that had bone fractures and were then injected with Staphylococcus aureus, CSA-90 increased rhBMP-2-induced bone formation. In addition, the mice receiving N8's compound were able to prevent the establishment of infection (p=0.012). Most mice that were not treated with CSA-90 were euthanized because of infection-induced localized osteolysis and poor health.
"This study, and many like it, demonstrate the versatility of our ceragenin platform, and encourage us to explore multiple applications for their use," said Dr. Michael Triplett, CEO of N8 Medical. "We have been investigating ceragenins for use in bone unions, particularly in the presence of infections and co-administration with low-dose rhBMP-2, and believe this is an extremely positive step forward in our pursuit of orthopaedic applications. These data are confirmation of our decision to continue to pursue broad clinical orthopedic applications for this technology including open fractures, spinal fusions, bone cement for orthopedic implants and many others."
N8 Medical, Inc., is a privately held, emerging pharmaceutical company focused on the development of a broad spectrum anti-infective therapy based upon ceragenins, a portfolio of synthetically produced small-molecule chemical compounds that mimic the activities of endogenous cationic antibacterial peptides that comprise the innate immune system. The company is currently focused on several applications for the ceragenin platform including treatment of chronic cystic fibrosis, pulmonary infections and the development of antimicrobial devices and coatings for the prevention of medical device-related hospital acquired infections. The company is based in Columbus, OH.
CONTACT: Jules Abraham JQA Partners, LLC jabraham@jqapartners.com 917-885-7378Help employers find you! Check out all the jobs and post your resume.